60 Degrees Pharmaceuticals (SXTP) Equity Average (2022 - 2025)
60 Degrees Pharmaceuticals (SXTP) has disclosed Equity Average for 4 consecutive years, with $3.3 million as the latest value for Q3 2025.
- On a quarterly basis, Equity Average fell 24.99% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 24.99% decrease, with the full-year FY2024 number at $4.4 million, up 145.65% from a year prior.
- Equity Average was $3.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $3.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $6.0 million in Q1 2024 to a low of -$23.3 million in Q4 2022.
- A 4-year average of -$4.9 million and a median of $3.3 million in 2025 define the central range for Equity Average.
- Peak YoY movement for Equity Average: soared 149.03% in 2024, then plummeted 36.79% in 2025.
- 60 Degrees Pharmaceuticals' Equity Average stood at -$23.3 million in 2022, then soared by 124.26% to $5.7 million in 2023, then dropped by 11.63% to $5.0 million in 2024, then crashed by 33.06% to $3.3 million in 2025.
- Per Business Quant, the three most recent readings for SXTP's Equity Average are $3.3 million (Q3 2025), $3.2 million (Q2 2025), and $4.0 million (Q1 2025).